Clinical trial · Observational
LTFU for All Cell and Gene Therapy Studies
A LOng-term Follow-up Master Protocol for Participants Who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)
NCT06194461CI-TRIAL-00091507LOCUSnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AZD0754 | Biological | — | UNRESOLVED |
| AZD5851 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- AZD5851
- description
- Follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884
- interventionNames
- Biological: AZD5851
- label
- AZD0754
- description
- Follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729
- interventionNames
- Biological: AZD0754
Primary outcomes (1)
- measure
- Incidence of specific AEs
- timeFrame
- Maximum of 15 years post dosing
- description
- To determine long-term safety of previous treatment with applicable cell and gene therapy products
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 130 Years
Show eligibility criteria text
Inclusion Criteria: 1. The participant has received a cell or gene therapy in another AstraZeneca protocol. 2. Provision of signed and dated, written informed consent before any study-specific procedures. Exclusion Criteria: Not applicable \-
References
Publications (0)
Data not yet available
No reference posted for this study.